WHO ICTRP trial
A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to…
PER-063-03 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-063-03 |
|---|---|
| Public title | A Phase IIIB Study Evaluating the Effect on Serum Lipids Following a Switch to Atazanavir in HIV Infected Subjects Evidencing Virologic Suppression on Their First PI-Based Antiretroviral Therapy. |
| Scientific title | PHASE III B, OPEN, RANDOMIZED AND MULTICENTRIC STUDY, TO EVALUATE THE EFFECT ON SERIC LIPIDS OF A CHANGE TO THE PROTEASE (IP) ATAZANAVIR INHIBITOR, IN PATIENTS INFECTED BY HIV-1 THAT SHOW VIROLOGICAL SUPPRESSION IN THEIR FIRST ANTIRETROVIRAL THERAPY THAT CONTAIN IP. |
| Primary sponsor | BRISTOL MYERS SQUIBB PERU S.A., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | III |
| Countries | Peru;United States |
| Conditions | -B24 Unspecified human immunodeficiency virus [HIV] disease Unspecified human immunodeficiency virus [HIV] disease;B24 ;Unspecified human immunodeficiency virus [HIV] disease |
| Interventions | Group name:Group 1 Type of group;1 N° of participants:100 Intervention(s) description:Atazanavir Next to the 2 current NRTIs (Immediate change group [Day 1]) Group name:Group 2 Type of group;1 N° of participants:100 Intervention(s)… |
| Registration date | Dec 19, 2003 |
| Target size | 14 |
| Secondary IDs | NCT00067782 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: